Drugs /

recombinant interleukin-12

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant form of the endogenous heterodimeric cytokine interleukin-12 with potential antineoplastic activity. Recombinant interleukin-12 binds to and activates its cell-surface receptor, stimulating the production of interferon-gamma (IFN) which, in turn, induces IFN-gamma-inducible protein-10 (IP-10) and so inhibits tumor angiogenesis. (NCI04)

Clinical Trials

View Clinical Trials for recombinant interleukin-12

Recombinant interleukin-12 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating recombinant interleukin-12, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for recombinant interleukin-12 clinical trials.

Breast carcinoma and malignant solid tumor are the most common diseases being investigated in recombinant interleukin-12 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Recombinant Interleukin-12
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating recombinant interleukin-12 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
interleukin 12, 8748, recombinant human interleukin-12 (il-12) cytokine, natural killer cell stimulatory factor, nm-il-12, ro 24-7472, recombinant human interleukin-12 (il-12) cytokine, 672423, 7103, cytotoxic lymphocyte maturation factor, interleukin-12, 6798, 187348-17-0, il-12, 6419, 6123, interleukin-12, cytotoxic lymphocyte maturation factor, recombinant interleukin-12, natural killer cell stimulatory factor
NCIT ID [1]:
C1380

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.